Concepedia

Anthony Conlon

AC

3

Publications

124

Citations

3

H-Index

2019

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Centre Hospitalier Universitaire Sainte-Justine

Université de Montréal

Research Institute Hospital 12 de Octubre

Anthony Conlon is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in vaccine development, vaccination, and medicine.

Top concepts

Publications per year

2019–2023

3

Publications

3

Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects

Stuart P. Adler, Nicole Lewis, Anthony Conlon et al. · The Journal of Infectious Diseases · 2019 · 71 citations · Full text

Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial

Rituparna Das, Daniel Blázquez‐Gamero, David I. Bernstein et al. · The Lancet Infectious Diseases · 2023 · 43 citations

, , +7

1048. Double-Blind, Randomized, Placebo-Controlled Phase 2b Multicenter Trial of V160, a Replication-Defective Human Cytomegalovirus (CMV) Vaccine

Rituparna Das, Daniel Blázquez‐Gamero, David I. Bernstein et al. · Open Forum Infectious Diseases · 2021 · 10 citations · Full text

, , +17

Rows per page

1–3 of 3